Susquehanna International Group’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.35M Buy
261,000
+59,700
+30% +$1.94M ﹤0.01% 3387
2025
Q4
$7.06M Buy
201,300
+63,500
+46% +$2.31M ﹤0.01% 3519
2025
Q3
$3.92M Buy
137,800
+63,400
+85% +$1.52M ﹤0.01% 4507
2025
Q2
$1.35M Sell
74,400
-12,100
-14% -$221K ﹤0.01% 6693
2025
Q1
$1.77M Buy
86,500
+47,900
+124% +$1.06M ﹤0.01% 5799
2024
Q4
$992K Buy
+38,600
New +$820K ﹤0.01% 6956

Other funds holding NAMS

Susquehanna International Group's NAMS Position: Q1 2026 in Review

Susquehanna International Group reduced its NewAmsterdam Pharma (NAMS) stake by 91% in Q1 2026, selling an estimated $5.79M and leaving 17,825 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #9326.

Susquehanna International Group first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.86M in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Susquehanna International Group held 17,825 shares of NewAmsterdam Pharma worth $571K as of Q1 2026.
  • Susquehanna International Group sold 177,810 NewAmsterdam Pharma shares in Q1 2026, an estimated $5.79M.
  • NewAmsterdam Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9326 holding.
  • Susquehanna International Group first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
  • Susquehanna International Group's NewAmsterdam Pharma position peaked at $6.86M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.